[Efficiency of uroprofit in women with chronic cystitis]

From September 2011 to December 2011, 40 women aged 20-68 years with chronic cystitis were examined. All patients were divided into two groups of 20 people depending on the type of treatment. Control group of patients received monotherapy with fosfomycin (monural), main group of patients--complex therapy with fosfomycin and biologically active supplement uroprofit. The results were evaluated at 1 and 2 months after initiation of therapy. Before and after treatment, all patients were examined, including standard laboratory tests, uroflowmetry, cystometry, and cystoscopy. It was shown that patients in main group have a rapid normalization of clinical manifestations and laboratory parameters, improvement of dynamics of the endoscopic picture. Thus, uroprofit has antibacterial, anti-inflammatory action, contributes to the normalization of urodynamics of the lower urinary tract, reduces the risk of relapses of chronic cystitis and can be recommended as a component of the treatment of acute exacerbations of chronic cystitis, as well as a drug for the prevention of disease in the disease-free interval.